Brueckner LM - Search Results

1

Instability at the FRA8I common fragile site disrupts the genomic integrity of the KIAA0146, CEBPD and PRKDC genes in colorectal cancer.

Brueckner LM, Hess EM, Schwab M, Savelyeva L. Brueckner LM, et al. Cancer Lett. 2013 Aug 9;336(1):85-95. doi: 10.1016/j.canlet.2013.04.007. Epub 2013 Apr 16. Cancer Lett. 2013. PMID: 23603433

2

The FRA2C common fragile site maps to the borders of MYCN amplicons in neuroblastoma and is associated with gross chromosomal rearrangements in different cancers.

Blumrich A, Zapatka M, Brueckner LM, Zheglo D, Schwab M, Savelyeva L. Blumrich A, et al. Among authors: brueckner lm. Hum Mol Genet. 2011 Apr 15;20(8):1488-501. doi: 10.1093/hmg/ddr027. Epub 2011 Jan 21. Hum Mol Genet. 2011. PMID: 21258086

3

Genomic rearrangements at the FRA2H common fragile site frequently involve non-homologous recombination events across LTR and L1(LINE) repeats.

Brueckner LM, Sagulenko E, Hess EM, Zheglo D, Blumrich A, Schwab M, Savelyeva L. Brueckner LM, et al. Hum Genet. 2012 Aug;131(8):1345-59. doi: 10.1007/s00439-012-1165-3. Epub 2012 Apr 5. Hum Genet. 2012. PMID: 22476624

4

Molecular characterization of common fragile sites as a strategy to discover cancer susceptibility genes.

Savelyeva L, Brueckner LM. Savelyeva L, et al. Among authors: brueckner lm. Cell Mol Life Sci. 2014 Dec;71(23):4561-75. doi: 10.1007/s00018-014-1723-z. Epub 2014 Sep 18. Cell Mol Life Sci. 2014. PMID: 25231336 Free PMC article. Review.

5

The FRA14B common fragile site maps to a region prone to somatic and germline rearrangements within the large GPHN gene.

Zheglo D, Brueckner LM, Sepman O, Wecht EM, Kuligina E, Suspitsin E, Imyanitov E, Savelyeva L. Zheglo D, et al. Among authors: brueckner lm. Genes Chromosomes Cancer. 2019 May;58(5):284-294. doi: 10.1002/gcc.22706. Epub 2018 Dec 20. Genes Chromosomes Cancer. 2019. PMID: 30411419

6

Low p14ARF expression in neuroblastoma cells is associated with repressed histone mark status, and enforced expression induces growth arrest and apoptosis.

Dreidax D, Gogolin S, Schroeder C, Muth D, Brueckner LM, Hess EM, Zapatka M, Theißen J, Fischer M, Ehemann V, Schwab M, Savelyeva L, Westermann F. Dreidax D, et al. Among authors: brueckner lm. Hum Mol Genet. 2013 May 1;22(9):1735-45. doi: 10.1093/hmg/ddt020. Epub 2013 Jan 23. Hum Mol Genet. 2013. PMID: 23343716

7

HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment.

Milde T, Lodrini M, Savelyeva L, Korshunov A, Kool M, Brueckner LM, Antunes AS, Oehme I, Pekrun A, Pfister SM, Kulozik AE, Witt O, Deubzer HE. Milde T, et al. Among authors: brueckner lm. J Neurooncol. 2012 Dec;110(3):335-48. doi: 10.1007/s11060-012-0978-1. Epub 2012 Oct 6. J Neurooncol. 2012. PMID: 23054560

8

CDK4 inhibition restores G(1)-S arrest in MYCN-amplified neuroblastoma cells in the context of doxorubicin-induced DNA damage.

Gogolin S, Ehemann V, Becker G, Brueckner LM, Dreidax D, Bannert S, Nolte I, Savelyeva L, Bell E, Westermann F. Gogolin S, et al. Among authors: brueckner lm. Cell Cycle. 2013 Apr 1;12(7):1091-104. doi: 10.4161/cc.24091. Epub 2013 Mar 5. Cell Cycle. 2013. PMID: 23462184 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8 results

Search Page

Filters